PE20121585A1 - ANTIBODIES AGAINST THE ERbB3 RECEPTOR ECTODOMINIUM AND ITS USES - Google Patents

ANTIBODIES AGAINST THE ERbB3 RECEPTOR ECTODOMINIUM AND ITS USES

Info

Publication number
PE20121585A1
PE20121585A1 PE2012000234A PE2012000234A PE20121585A1 PE 20121585 A1 PE20121585 A1 PE 20121585A1 PE 2012000234 A PE2012000234 A PE 2012000234A PE 2012000234 A PE2012000234 A PE 2012000234A PE 20121585 A1 PE20121585 A1 PE 20121585A1
Authority
PE
Peru
Prior art keywords
seq
amino acid
acid sequence
antibody
ectodominium
Prior art date
Application number
PE2012000234A
Other languages
Spanish (es)
Inventor
Birgit Schoeberl
Ulrik Nielsen
Michael Feldhaus
Original Assignee
Merrimack Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=43607614&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PE20121585(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Merrimack Pharmaceuticals Inc filed Critical Merrimack Pharmaceuticals Inc
Publication of PE20121585A1 publication Critical patent/PE20121585A1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/32—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Abstract

SE REFIERE A UN ANTICUERPO CONTRA ErbB3 QUE COMPRENDE: A) UNA REGION VARIABLE DE CADENA PESADA QUE TIENE UNA SECUENCIA DE AMINOACIDOS DE SEQ ID Nº 1 Y COMPRENDE UNA CDRH1 QUE TIENE LA SECUENCIA DE AMINOACIDOS DE SEQ ID Nº 7, UNA CDRH2 QUE TIENE LA SECUENCIA DE AMINOACIDOS DE SEQ ID Nº 8, Y UNA CDRH3 QUE TIENE LA SECUENCIA DE AMINOACIDOS DE SEQ ID Nº 9; Y B) UNA REGION VARIABLE DE CADENA LIGERA QUE TIENE UNA SECUENCIA DE AMINOACIDOS DE SEQ ID Nº 2 Y COMPRENDE UNA CDRL1 QUE TIENE LA SECUENCIA DE AMINOACIDOS DE SEQ ID Nº 10, UNA CDRL2 QUE TIENE LA SECUENCIA DE AMINOACIDOS DE SEQ ID Nº 11, Y UNA CDRL3 QUE TIENE LA SECUENCIA DE AMINOACIDOS DE SEQ ID Nº 12. TAMBIEN SE REFIERE A UN METODO DE TRATAMIENTO DE CARCINOMA RENAL, CANCER DE PROSTATA, CANCER DE OVARIO Y CANCER PULMONAR QUE COMPRENDE ADMINISTRAR EL ANTICUERPO CONTRA ErbB3 Y OTRO COMPUESTO TAL COMO ERLOTINIB, TAXOL O CISPLATINO PARA OBTENER UN EFECTO SINERGICO EN LA SUPRESION DEL CRECIMIENTO DEL TUMORIT REFERS TO AN ANTIBODY AGAINST ErbB3 WHICH INCLUDES: A) A HEAVY CHAIN VARIABLE REGION THAT HAS AN AMINO ACID SEQUENCE OF SEQ ID NO 1 AND INCLUDES A CDRH1 THAT HAS THE AMINO ACID SEQUENCE OF SEQ ID NO 7, A CDRH2 THAT HAS AMINO ACID SEQUENCE OF SEQ ID No. 8, AND A CDRH3 HAVING THE AMINO ACID SEQUENCE OF SEQ ID No. 9; AND B) A LIGHT CHAIN VARIABLE REGION THAT HAS AN AMINO ACID SEQUENCE OF SEQ ID NO. 2 AND INCLUDES A CDRL1 HAVING THE AMINO ACID SEQUENCE OF SEQ ID NO. 10, A CDRL2 HAVING THE AMINO ACID SEQUENCE OF SEQ ID NO. 11, AND A CDRL3 THAT HAS THE SEQ ID NO. 12 AMINO ACID SEQUENCE ALSO REFERS TO A TREATMENT METHOD FOR RENAL CARCINOMA, PROSTATE CANCER, OVARIAN CANCER AND LUNG CANCER THAT INCLUDES ADMINISTERING THE ANTIBODY, AS ANOTHER COMPUTER, AS ANTIBODY ERL3 TAXOL OR CISPLATINE TO OBTAIN A SYNERGIC EFFECT IN THE SUPPRESSION OF TUMOR GROWTH

PE2012000234A 2009-08-21 2010-08-23 ANTIBODIES AGAINST THE ERbB3 RECEPTOR ECTODOMINIUM AND ITS USES PE20121585A1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US23579909P 2009-08-21 2009-08-21

Publications (1)

Publication Number Publication Date
PE20121585A1 true PE20121585A1 (en) 2012-11-29

Family

ID=43607614

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2012000234A PE20121585A1 (en) 2009-08-21 2010-08-23 ANTIBODIES AGAINST THE ERbB3 RECEPTOR ECTODOMINIUM AND ITS USES

Country Status (21)

Country Link
EP (1) EP2467164A2 (en)
JP (1) JP5752687B2 (en)
KR (1) KR20120059568A (en)
CN (1) CN103002912A (en)
AU (1) AU2010284018C1 (en)
BR (1) BR112012003809A2 (en)
CA (1) CA2771744A1 (en)
CR (1) CR20120108A (en)
DO (1) DOP2012000044A (en)
EA (1) EA201200195A1 (en)
EC (1) ECSP12011740A (en)
IL (1) IL218097A0 (en)
IN (1) IN2012DN01518A (en)
MA (1) MA33582B1 (en)
MX (1) MX336091B (en)
NI (1) NI201200027A (en)
PE (1) PE20121585A1 (en)
SG (1) SG178509A1 (en)
TN (1) TN2012000057A1 (en)
WO (1) WO2011022727A2 (en)
ZA (1) ZA201201195B (en)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SI2129396T1 (en) 2007-02-16 2013-12-31 Merrimack Pharmaceuticals, Inc. Antibodies against erbb3 and uses thereof
EP2719708B1 (en) * 2009-11-13 2017-10-25 Daiichi Sankyo Europe GmbH Material and methods for treating or preventing HER-3 associated diseases
HUE029026T2 (en) 2009-12-22 2017-01-30 Roche Glycart Ag ANTI-HER3 Antibodies and uses thereof
EA201201186A1 (en) 2010-03-11 2013-11-29 Мерримак Фармасьютикалс, Инк. USE OF ERBB3 INHIBITORS IN THE TREATMENT OF NEGATIVE AND BASAL-LIKE BREAST CANCER TREATMENT
BR112012025730B1 (en) 2010-04-09 2020-12-08 Aveo Pharmaceuticals, Inc isolated antibody that binds to human erbb3, its uses, its production process and expression vector
EA036314B1 (en) 2010-08-20 2020-10-26 Новартис Аг Antibodies for epidermal growth factor receptor 3 (her3)
TW201302793A (en) 2010-09-03 2013-01-16 Glaxo Group Ltd Novel antigen binding proteins
IT1402149B1 (en) * 2010-10-04 2013-08-28 Ist Fisioterap Ospitalroma USE OF A PHOSPHOPEPTIDE WHICH IS ABLE TO BLOCK THE HER3 / P85 INTERACTION FOR THE TREATMENT OF HER2 EXPRESSION TUMORS.
WO2012059858A1 (en) * 2010-11-01 2012-05-10 Symphogen A/S Anti-her3 antibodies and compositions
CA2833643A1 (en) 2011-04-19 2012-10-26 Merrimack Pharmaceuticals, Inc. Monospecific and bispecific anti-igf-1r and anti-erbb3 antibodies
CN103781800A (en) 2011-06-20 2014-05-07 协和发酵麒麟株式会社 Anti-erbB3 antibody
US9273143B2 (en) 2011-09-30 2016-03-01 Regeneron Pharmaceuticals, Inc. Methods and compositions comprising a combination of an anti-ErbB3 antibody and an anti-EGFR antibody
MX357391B (en) 2011-09-30 2018-07-06 Regeneron Pharma Anti-erbb3 antibodies and uses thereof.
WO2013052745A1 (en) 2011-10-06 2013-04-11 Aveo Pharmaceuticals, Inc. Predicting tumor response to anti-erbb3 antibodies
US9637543B2 (en) 2011-11-09 2017-05-02 The Uab Research Foundation HER3 antibodies and uses thereof
EA036739B1 (en) 2011-12-05 2020-12-15 Новартис Аг Antibodies for epidermal growth factor receptor 3 (her3)
US20150037336A1 (en) * 2012-02-22 2015-02-05 U3 Pharma Gmbh Combination of hb-egf binding protein and egfr inhibitor
US9180185B2 (en) 2013-01-11 2015-11-10 Hoffman-La Roche Inc. Combination therapy of anti-HER3 antibodies
US20160232293A1 (en) * 2013-10-17 2016-08-11 Sanford-Burnham Medical Research Institute Drug sensitivity biomarkers and methods of identifying and using drug sensitivity biomarkers
EP3087394A2 (en) 2013-12-27 2016-11-02 Merrimack Pharmaceuticals, Inc. Biomarker profiles for predicting outcomes of cancer therapy with erbb3 inhibitors and/or chemotherapies
US10844127B2 (en) 2014-02-28 2020-11-24 Merus N.V. Antibodies that bind EGFR and ErbB3
CN105367657B (en) * 2014-08-14 2019-09-13 上海生物制品研究所有限责任公司 Anti- HER3 antibody, its preparation method and its application
US10526416B2 (en) 2014-09-08 2020-01-07 Yeda Research And Development Co. Ltd. Anti-HER3 antibodies and uses of same
WO2016038610A1 (en) 2014-09-08 2016-03-17 Yeda Research And Development Co. Ltd. Compositions and methods for treating cancer resistant to a tyrosine kinase inhibitor (tki)
US10184006B2 (en) 2015-06-04 2019-01-22 Merrimack Pharmaceuticals, Inc. Biomarkers for predicting outcomes of cancer therapy with ErbB3 inhibitors
MX2018004988A (en) 2015-10-23 2018-11-09 Merus Nv Binding molecules that inhibit cancer growth.
BR112019020508A2 (en) 2017-03-31 2020-08-04 Merus N.V. bispecific antibodies binding to erbb-2 and erbb3 for use in the treatment of cells that have an nrg1 fusion gene
EP3665200A4 (en) 2017-08-09 2021-04-28 University of Saskatchewan Her3 binding agents and uses thereof
JP2020530028A (en) 2017-08-09 2020-10-15 メルス ナムローゼ フェンノートシャップ Antibodies that bind to EGFR and cMET
GB201804094D0 (en) * 2018-03-14 2018-04-25 Ultrahuman Thirteen Ltd ERBB3 Binding agents
US20210246223A1 (en) * 2018-06-22 2021-08-12 Crd Pharmaceuticals Inc ANTI-HER3 Antibody and uses thereof
AU2021360625A1 (en) * 2020-10-14 2023-06-01 Jiangsu Hengrui Pharmaceuticals Co., Ltd. Anti-her3 antibody and anti-her3 antibody-drug conjugate and medical use thereof
WO2023198138A1 (en) * 2022-04-13 2023-10-19 上海翰森生物医药科技有限公司 Antibody or antigen-binding fragment thereof and medical use thereof

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SI2129396T1 (en) * 2007-02-16 2013-12-31 Merrimack Pharmaceuticals, Inc. Antibodies against erbb3 and uses thereof

Also Published As

Publication number Publication date
CN103002912A (en) 2013-03-27
SG178509A1 (en) 2012-04-27
KR20120059568A (en) 2012-06-08
IN2012DN01518A (en) 2015-06-05
EP2467164A2 (en) 2012-06-27
NI201200027A (en) 2013-01-29
TN2012000057A1 (en) 2013-09-19
WO2011022727A2 (en) 2011-02-24
BR112012003809A2 (en) 2019-09-24
AU2010284018B2 (en) 2014-06-05
AU2010284018C1 (en) 2015-10-15
ECSP12011740A (en) 2013-02-28
JP5752687B2 (en) 2015-07-22
DOP2012000044A (en) 2012-06-30
CR20120108A (en) 2012-06-05
EA201200195A1 (en) 2012-12-28
JP2013506622A (en) 2013-02-28
AU2010284018A1 (en) 2012-03-22
CA2771744A1 (en) 2011-02-24
MX2012002172A (en) 2012-05-29
IL218097A0 (en) 2012-04-30
MA33582B1 (en) 2012-09-01
ZA201201195B (en) 2015-07-29
MX336091B (en) 2016-01-08
WO2011022727A3 (en) 2013-06-27

Similar Documents

Publication Publication Date Title
PE20121585A1 (en) ANTIBODIES AGAINST THE ERbB3 RECEPTOR ECTODOMINIUM AND ITS USES
AR087405A1 (en) METHODS TO TREAT CANCER BY THE USE OF ANTAGONISTS OF UNION TO THE AXIS PD-1 AND INHIBITORS OF MEK
PE20181326A1 (en) ANTIBODIES THAT SPECIFICALLY BIND PD-1 AND ITS USES
AR077595A1 (en) COMBINATION TREATMENTS
PE20142242A1 (en) ANTI-CD27 HUMAN ANTIBODIES, METHODS, AND USES
AR091220A1 (en) METHODS TO TREAT CANCER USING ANTAGONISTS OF UNION TO PD-1 AXIS AND ANTIGONISTS OF VEGF
NZ602084A (en) Use of erbb3 inhibitors in the treatment of triple negative and basal-like breast cancers
AR086579A1 (en) PROTEINS OF UNION TO ANTIGEN
CY1119410T1 (en) OPTIMIZED monoclonal antibodies against the TFPI inhibitor (TFPI)
AU2011338383A8 (en) Treatment of HER2-positive cancer with paclitaxel and trastuzumab-MCC-DM1
PE20121579A1 (en) BINDING PROTEINS TO THE HUMAN IL-23 ANTIGEN
AR094849A1 (en) COMBINED THERAPY INVOLVING DIRECTED ANTIBODIES AGAINST CLAUDINE 18.2 FOR CANCER TREATMENT
SG10201906075VA (en) Methods of treating cancer
AR086044A1 (en) ANTIBODIES THAT SPECIFICALLY JOIN A C-KIT EXTRACELLULAR DOMAIN AND USES OF THE SAME
UA106890C2 (en) LibreOfficeantibody to CDCP1
CL2014001282A1 (en) Use of an immunoconjugate of an antibody directed against the epidermal growth factor receptor (egfr) for the treatment of cancer resistant to the treatment directed against egfr, where the immunoconjugate is an antibody bound to a cytotoxic agent.
EA032934B1 (en) Use of a combination comprising an antibody specifically recognizing cd38 and cyclophosphamide
NZ606195A (en) Methods and compositions for liver cancer therapy
PE20150025A1 (en) ANTIBODIES AND IMMUNOCONJUGATES AGAINST LY6E AND METHODS OF USE
BR112014024017A8 (en) METHODS FOR TREATMENT OF A TYPE OF CANCER, FOR TREATMENT OF CARCINOMA, FOR SELECTING A THERAPY AND FOR QUANTIFICATION AND HER3 INHIBITORS
PE20161389A1 (en) ANTI-CD38 ANTIBODIES FOR THE TREATMENT OF ACUTE LYMPHOBLASTIC LEUKEMIA
NZ592369A (en) Fibroblast growth factor receptor-3 (fgfr-3) inhibitors and methods of treatment
GB201114051D0 (en) Compounds and their uses
WO2011146568A8 (en) Predicting response to a her inhibitor
AR070821A1 (en) ANTI-TYRP1 ANTIBODY (HUMAN ANTITIROXIN)

Legal Events

Date Code Title Description
FX Voluntary withdrawal